 |
|
|
|
September 2000 Cover
|
|
New research presented at the 13th International AIDS Conference showed that a class of drugs known as fusion inhibitors was well-tolerated by patients who took them in combination with other antiretroviral drugs. A
48-week Phase II/III trial of T-20, which is made by Trimeris in partnership with Roche, indicated that 56 percent of the patients who completed the treatment had substantial reductions of the amount of HIV in their blood.
The researchers noted that while the data shows promise, further research is needed. One downside to T-20 is that it must be injected, but Roche noted that it hopes to work on an oral form of the drug with Progenics
Pharmaceuticals.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
